R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B
Diffuse Large B-cell Lymphoma, Follicular Lymphoma Grade 3B
About this trial
This is an interventional treatment trial for Diffuse Large B-cell Lymphoma focused on measuring diffuse large B-cell lymphoma, follicular lymphoma grade 3B
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed de novo diffuse large B-cell lymphoma or follicular lymphoma grade 3B
- Age>=16 y.o.,<=80 y.o.
- ECOG < 3
- No past history of malignancy
- Radiologically measurable disease, CT imaging in screening showing 2 or more clearly demarcated lesions with a largest diameter > 1.5 cm, or 1 clearly demarcated lesion with a largest diameter > 2.0 cm.
- Life expectancy>6 months
- Informed consented
Exclusion Criteria:
- Chemotherapy before
- Bone marrow transplantation before
- History of malignancy
- Active infectious disease requiring general antibiotics, anti-fungal or anti-virus therapy
- Uncontrollable cardio-cerebral vascular, coagulative, autoimmune, serious infectious disease
- Primary cutaneous, CNS, mediastinal DLBCL
- LVEF≤50%
- Other uncontrollable medical condition that may that may interfere the participation of the study
Lab at enrollment(unless caused by lymphoma)
- Neutrophile<1.5*10^9/L
- Platelet<80*10^9/L
- Hemoglobulin<100g/L
- ALT or AST >2*ULN,AKP or bilirubin >1.5*ULN
- Creatinine>1.5*ULN
- Not able to comply to the protocol for mental or other unknown reasons
- Pregnant or lactation
- Active liver or biliary disease
- If HbsAg positive, should check HBV DNA, DNA positive patients cannot be enrolled. If HBsAg negative but HBcAb positive (whatever HBsAb status), should check HBV DNA,DNA positive patients cannot be enrolled.
- HIV infection
Sites / Locations
- Southwest Hospital
- Fujian Medical University Union Hospital
- Guangdong General Hospital
- Henan Cancer Hospital
- Tongji Hospital
- Jiangsu Province Hospital
- The first hospital of China medical university
- Shanxi Provincial Tumor Hospital
- West China Hospital
- Institute of Hematology and Blood Diseases Hospital
- Shandong Provincal Hospital
- Shanghai Ruijin Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
R-CHOP-50
R-CEOP-70
R-CEOP-90
R-CHOP-50 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 50mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
R-CEOP-70 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 70mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.
R-CEOP-90 (Rituximab 375 mg/m2 d1+Cyclophosphomide 750mg/m2 d2+Adriamycin 90mg/m2 d2+vincristine 1.4mg/m2 d2+Prednisone 60 mg/m2 d2-6) every 21 days for 6 cycles, followed by Rituximab 375 mg/m2 every 21 days for 2 cycles.